We help the NHS buy from you
Helping pharmaceutical companies navigate NHS decision-making so adoption becomes possible.
Why strong evidence isn’t enough
Many effective medicines fail to gain traction in the NHS because their value is presented in ways that do not reflect how decisions are made in practice.
- Formularies are secured but uptake stalls
- Value propositions that should resonate fail to land
- Teams work hard, but adoption does not follow
In the NHS, evidence alone rarely drives use. Adoption depends on how well a medicine fits patient pathways, service pressures and commissioning realities.
At Cheemia, we start by understanding how the system actually works and where change is possible.
Alignment before activity
Cheemia was founded to close the gap between strong products and how the NHS actually works.
Before any activity begins, we assess whether adoption is realistically possible within NHS systems.
We focus on:
- Where NHS decisions are really made
- What matters to the people making them
- Whether formulary adoption is structurally possible
We don’t help companies sell to the NHS.
We help the NHS buy from them.
“In one devolved NHS region, market share increased from 9% to over 50% within 24 months following a targeted access strategy.”
Market Access and Pull-Through Expertise
What we do
Insight-led support to help pharmaceutical companies secure NHS formulary access and achieve sustainable adoption. We focus effort where NHS uptake is realistically achievable and align product value with NHS priorities.
Structured programmes that help marketing, medical and commercial teams work together more effectively to create customer-focused engagement. Through a series of working sessions, teams build customer-centric habits and stronger cross-functional engagement.
A self-paced programme built around seven habits for effective omnichannel engagement. Designed for busy field teams, it helps strengthen HCP conversations while fitting around day-to-day work.
Built around how the NHS actually works
Understand the system
We identify what is preventing adoption.
Focus where change is possible
We assess structural barriers before time and budget are committed.
Support real-world uptake
We align product value with NHS pathways, budgets and decision-making.
Mehrnaz Campbell — Founder of Cheemia | Author of The Omni Advantage
Mehrnaz is a keynote speaker and founder of Cheemia, speaking internationally on HCP engagement, market access and behavioural change in pharmaceutical organisations.